Staged approach used in biomarker discovery and prioritization and algorithm development.

*130 biomarkers had adequate measurability to advance to studies of clinical disease activity.†Patients and samples in Study IV represent a subset of those evaluated in Study II.‡In addition to the 25 biomarkers that were subsequently advanced to model development (Stage 3), this study also examined other serum biomarkers of potential interest to prediction of structural damage progression, some of which overlapped with biomarkers considered for disease activity prediction.